Oxford Biomedica (LON:OXB) Shares Down 5.1% – Here’s Why

Shares of Oxford Biomedica plc (LON:OXB) traded down 5.1% on Wednesday . The stock traded as low as GBX 424 and last traded at GBX 424. Approximately 2,402,807 shares were traded during mid-day trading, an increase of 122% from the average session volume of 1,081,424 shares. The stock had previously closed at GBX 447.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on OXB shares. Royal Bank Of Canada reiterated an “outperform” rating and set a GBX 900 price target on shares of Oxford Biomedica in a report on Tuesday. Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a GBX 595 price objective on shares of Oxford Biomedica in a report on Wednesday. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a GBX 8.27 price objective on shares of Oxford Biomedica in a research report on Tuesday, June 2nd. Four equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of GBX 580.85.

Oxford Biomedica Price Performance

The company has a debt-to-equity ratio of 162.16, a current ratio of 2.20 and a quick ratio of 1.67. The stock has a market capitalization of £517.63 million, a P/E ratio of -15.89 and a beta of 1.10. The stock’s fifty day moving average is GBX 559.05 and its 200-day moving average is GBX 601.08.

Oxford Biomedica Company Profile

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.